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Abstract
Background: Paracetamol and ibuprofen are the most commonly used medications for fever and pain
management in children. While the efficacy appears similar with both drugs, there are contradictory findings related
to adverse events. In particular, incidence of wheezing and asthma among children taking paracetamol compared
to ibuprofen, remain unsettled.
Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) that compared wheezing and
asthma exacerbations in children taking paracetamol versus ibuprofen. A comprehensive search was conducted in
five databases. RCTs reporting on cases of wheezing or asthma exacerbations in infants or children after the
administration of paracetamol or ibuprofen were included. The pooled effect size was estimated using the Peto’s
odds ratio.
Results: Five RCTs with 85,095 children were included in the analysis. The pooled estimate (OR 1.05; 95%CI 0.76–
1.46) revealed no difference in the odds of developing asthma or presenting an exacerbation of asthma in children
who received paracetamol compared to ibuprofen. When the analysis was restricted to RCTs that examined the
incidence of asthma exacerbation or wheezing, the pooled estimate remained similar (OR 1.01; 95%CI 0.63–1.64).
Additional bias adjusted quality effect sensitivity model yielded similar results (RR 1.03; 95%CI 0.84–1.28).
Conclusion: Although, Ibuprofen and paracetamol appear to have similar tolerance and safety profiles in terms of
incidence of asthma exacerbations in children, we suggest high quality trials with clear definition of asthma
outcomes after receiving ibuprofen or paracetamol at varying doses with longer follow-up are warranted for any
conclusive finding.
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Background
Paracetamol, also known as acetaminophen, is one of
most commonly used over-the-counter medication to
treat pain and fever. Paracetamol is perceived as a safe
medication to control pain and fever in children, yet evi-
dence from multiple epidemiological studies have shown a
potential association between its use and asthma. Epi-
demiological studies have found an increased risk across
difference populations as well as a dose-response relation-
ship [1–8]. A meta-analysis found the odds of wheezing
doubles (OR 1.97; 95%CI 1.51–2.56) in children exposed
to paracetamol [9]. On the other hand, a recent study by
Walsh and Rothenberg found a decreased in risk of
wheezing in children when exposed to paracetamol for an
episode of bronchiolitis or respiratory tract infection [10].
The increasing evidence accumulated over the past 30
years about the risk of asthma exacerbations associated
with paracetamol has led clinicians to recommend a
change in practice, particularly in children [11–13]. Among
the alternatives to treat pain and fever in children, one that
stands out is ibuprofen. A meta-analysis by Pierce and
Voss found that ibuprofen is more effective in reducing
pain and fever than paracetamol in paediatric population
[14]. They also reported that ibuprofen and paracetamol
had similar rates of adverse events; however, they did not
assess the risk of asthma [14]. Ibuprofen as a nonsteroidal
anti-inflammatory drug (NSAID), inhibits cyclooxygenase
(COX) and reduces prostaglandin synthesis. That in turn
causes reduction in fever, inflammation, and pain. How-
ever, the inhibition of the COX pathway can also activate
the lipoxygenase pathway, leading to an increase in leuko-
triene synthesis, and resulting in bronchospasms and
asthma exacerbation [15].
The aim of this meta-analysis is to quantify the risk of
wheezing and asthma exacerbations in paediatric popu-
lation taking ibuprofen and paracetamol. Our findings
are expected to help guide the paediatricians in manage-
ment of fever and pain and drug choices.
Methods
Findings from this systematic review and meta-analysis
are presented following the recommendations from the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA). The review was registered
with the International Prospective Register of Systematic
Reviews (CRD42017080165).
Search strategy and study selection
The search strategy was conducted in PubMed, Science
Citation Index, Embase, Cochrane library, and Clinical-
Trials.gov. The following search terms were included
(paracetamol OR tylenol OR acetaminophen) AND ibu-
profen AND (pediatrics OR children OR infants). All data-
bases were searched from their inception until September
2017. The search was updated in July 2019 and was sup-
plemented with a PubMed similarity search as well as a
forwards and backwards citation search for the articles in-
cluded in the meta-analysis. The references lists from rele-
vant systematic reviews and meta-analyses were hand
searched.
Eligible studies were RCTs conducted in humans that in-
cluded paracetamol and ibuprofen within their study arms.
To be considered for inclusion, the RCTs had to include
children (≤12 years) and reported the number of cases of
wheezing, asthma and/or asthma exacerbations. The out-
come of interest (i.e.wheezing, asthma or asthma exacerba-
tion) could be reported either as the primary or secondary
outcome or as an adverse event in the RCT. Studies were
excluded if the study arms included co-interventions (e.g.
paracetamol plus codeine). No language restriction was ap-
plied. Two authors (MS and JN) independently screened
the articles. Disagreement was resolved through consensus.
Data extraction and quality assessment
A spreadsheet was used for data extraction. The following
items were extracted by one of the authors (MS) author,
year of publication, study setting and characteristics of the
study population, follow-up time, characteristics of the in-
terventions (e.g. dose of medication), sample size, and
number of cases of wheezing or asthma excerbations. The
extracted data was cross-checked by a second author (JD).
The same two authors assessed the risk of bias of the
RCTs using the Cochrane collaboration’s tool for assessing
the bias in randomized trials [16].
Statistical analysis
The effect measure of interest was the odds ratio (OR)
of developing asthma exacerbations or wheezing after
exposure to paracetamol compared to ibuprofen. The
pooled OR was estimated using the Peto’s method as the
outcome was rare (three arms contained zero events).
Statistical heterogeneity among studies was assessed
using the I2, an I2 > 50% was considered substantial
between-study heterogeneity. Sensitivity analyses were
conducted by excluding studies that measured exacerba-
tion of asthma as their outcome as well as including the
studies’ quality information (i.e. risk of bias) into the
model through the quality effects (QE) model [17]. Pub-
lication bias was investigated using the Doi plot and LFK
index [18]. The analysis was conducted in MetaXL ver-
sion 5.3 (EpiGear Int Pty Ltd.; Sunrise Beach; Australia;
http://www.epigear.com).
Results
Selection of studies
The search identified 655 publications, 104 articles
remained after title and abstract screening and the full
text of the articles were examined to assess their
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eligibility. Eight publications met the inclusion criteria.
Four publications [8, 19–21] used subsets of the Boston
University Fever Study data, only the publication with
larger sample size [19] was included in the meta-
analysis. Therefore, five RCTs with 85,095 children were
included in the meta-analysis (Fig. 1).
Characteristics of included studies
Four RCTs were conducted in hosptails [22–25], while one
was conducted in paediatric and family medicine practices
[19]. The age of the participants ranged from 2months to
12 years with a mean age between 21 and 40months. Four
RCTs [19, 22, 23, 25] included only febrile children, their
outcome of interest was episodes of asthma excerbations
after the administration of paracetamol or ibuprofen, and
had a relative short follow-up period ranging from 6 h to
28 days. Sheehan et al. [24] included afebrile children with
asthma, thus the outcome of interest was exacerbation of
asthma or wheezing after receiving paracetamol or ibupro-
fen, and had a longer follow-up period of 48 weeks
(Table 1). Overall, the risk of bias was low among the
RCTs, the most common deficiency was blinding of out-
come assessment, followed by allocation concealment and
blinding of participants and personnel (Table 2).
Quantitative analysis
The point estimates of two RCTs indicated lower risk of
asthma exacerbations with paracetamol [22, 25], two
RCTs point estimates indicated no difference [19, 24],
while the last RCT point estimate favoured the use of
ibuprofen [23]. Moderate statistical heterogeneity (I2 =
36%) among the five RCTs was observed. The pooled
estimate (OR 1.05; 95%CI 0.76–1.46) revealed that there
is no difference in the odds of developing asthma exacer-
bations or wheezing in children who received paraceta-
mol compared to ibuprofen (Fig. 2). When the analysis
was restricted to RCTs that examined the episodes of
asthma or exacerbations of asthma as their outcome of
interest, the pooled estimate did not change (OR 1.01;
95%CI 0.63–1.64). The QE model using the additional
information from the quality assessment of each studies
yielded similar results (RR 1.03; 95%CI 0.84–1.28). The
Doi plot and the LFK index (− 2.14) indicated major
asymmetry in favour of RCTs reporting less episodes of
asthma exacerbations with paracetamol compared to
ibuprofen (Fig. 3).
Discussion
Although efficacy, safety, and tolerability of ibuprofen
and paracetamol in children have been investigated [14,
26]; only few studies have investigated the association
between asthma and the use of these medications. After
a comprehensive search, only five relevant RCTs were
identified and included in this review, which points out
to the paucity of data in this area of research. The
pooled estimate indicates that there is no statistical nor
clinically important differences between the use of ibu-
profen or paracetamol in the paediatric population in re-
lation to asthma morbidity.
These null findings appear to be similar even among
very young children. Lesko and Mitchell used a subset of
their original data and compared the safety profile of these
medications in children less than 2 years [21]. They found
that the risk of hospital admissions due to asthma/
Fig. 1 PRISMA flow diagram
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bronchiolitis was similar with ibuprofen and paracetamol.
Such a negative findings support the theory that risk of
asthma morbidity is similar with ibuprofen and paraceta-
mol. Their study also showed that the effect is not modi-
fied by the age. This is particular pertinent as the sample
size in their study (n = 27,065) was large with sufficient
power to detect even a small differences, if existed be-
tween drugs.
Potential biological mechanisms that underpin the role of
these drugs in asthma exacerbations have been postulated.
Paracetamol is related to impaired lung function and
asthma through a number of possible mechanisms; first
being through oxidative stress. As paracetamol can lead to
reduction of antioxidant glutathione concentration in the
lungs, that can increase the oxidative stress in asthmatic
patients. Bronchospasm through leukotriene release can be
triggered by reactive oxygen species, which can greatly
affect sensitive asthmatic patients [27, 28]. A second mech-
anism is related to the lack of COX-2 inhibition by para-
cetamol which can trigger immune mediated response
Table 2 Assessment of risk of bias of the included randomised controlled trials
Author, year Random
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding
of outcome
assessment
Incomplete
outcome data
Selective
reporting
Exposure
assessmenta
Outcome
assessmenta
Lesko et al.
1995 [19]
Low risk Low risk Low risk Low risk Low risk Low risk High risk High risk
Luo et al.
2017 [22]
Low risk Low risk High risk High risk Low risk Low risk Low risk Low risk
McIntyre and Hull
1996 [23]
Low risk High risk High risk High risk Low risk Low risk Low risk Low risk
Sheehan et al.
2016 [24]
Low risk Low risk Low risk Low risk High risk Low risk Unclear Low risk
Wong et al.
2001 [25]
Low risk High risk Low risk High risk Low risk Low risk Low risk Low risk
a Exposure and outcome assessment were considered low risk if the information was obtained from medical records or directly recorded by the investigators, and
high risk if it was self-reported by the parents or guardians of the children
The other items of the risk of bias were classified as low or high risk following the Cochrane collaboration’s tool for assessing the bias in randomized trials [16]
Table 1 Characteristics of the included randomised controlled trials
Author, year Setting Study population Proportion of
females (%)
Mean/median
age (months)
Follow-up
duration (days)
Dose of
paracetamol/
ibuprofen
Number of
participants
paracetamol/
ibuprofen
Cases of asthma
paracetamol/
ibuprofen
Lesko et al.
1995 [19]
Outpatient
paediatric and
family medicine
practice
throughout
the US (1991–1993)
Children aged 6
months to 12 years
with acute febrile
illness
(Boston University
Fever Study)
48 40 28 12 mg/kg /
5-10 mg/kg
28,130 / 55,
739
24 / 44
Luo et al.
2017 [22]
Tertiary hospital
in China (2013–2014)
Febrile children
aged 6 months to
5 years attending
the emergency
room
40 30 5 10 mg/kg /
10 mg/kg
158 / 157 0 / 2
McIntyre
and Hull
1996 [23]
Tertiary hospital
in the UK
Febrile children
aged 2 months to
12 years
41 21 3 50 mg/kg /
20 mg/kg
74 / 76 2 / 0
Sheehan et al.
2016 [24]
18 hospitals in the
US (2013–2015)
Children aged 1 to
6 years receiving
long-term step 2
asthma-controller
therapy
(The Acetaminophen
versus Ibuprofen in
Children with Asthma
trial)
40 40 336 15 mg/kg /
9.4 mg/kg
150 / 150 74 / 70a
Wong et al.
2001 [25]
University hospitals in
Argentina, Mexico,
Chile, and Brazil (1998)
Febrile children aged
6 months to 6 years
46 30 0.25 12 mg/kg /
5-10 mg/kg
210 / 209 0 / 2
aCases of asthma exacerbations
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through T helper cells which increase sensitivity to an aller-
gic tendency to different stimuli. Another study suggested
that the frequent use of paracetamol can result in consist-
ent decrease in intracellular glutathione levels which can be
linked to asthma morbidity [29, 30]. On the other hand,
ibuprofen were thought to induce asthma symptoms
through COX-1 enzyme blockage which increases
thromboxane production and decreases production of
prostaglandins that have anti-inflammatory effect, leading
to an increased release of pro-inflammatory leukotrienes
which are chemical triggers for severe asthma exacerba-
tions and allergy-like symptoms [31]. Although, the plaus-
ible biological pathways for paracetamol and ibuprofen to
produce bronchospasms are different, findings from our
study revealed that the net effect in bronchospasms is
similar between both medications.
Our findings should be understood in the light of a
number of limitations. The follow-up duration in four out
of the five RCTs included in the meta-analysis was ≤28
days. The association between medication exposure and
diagnosis of asthma may require a longer follow-up period
as symptoms could develop after 4 weeks. A large RCT,
PIPPA Tamariki (https://pippatamariki.ac.nz) with a pro-
posed follow-up of 6 year will provide more evidence
about the risk of developing asthma in children exposed
paracetamol compared to children exposed to ibuprofen
within their first year of life. Asthma was not the primary
or secondary outcome and was reported as an adverse
event in four RCTs. The severity of morbidity from
asthma was not consistent across all studies as one RCT
included “mild wheezing” [23], while another used asthma
exacerbation that required systemic glucocorticoids as the
outcome of interest [24]. There were also variation in the
dose of the interventions between RCTs as well as in the
follow up time that ranged from 6 h to 48 weeks.
Conclusions
Our finding of similar tolerance and safety profiles of
paracetamol and ibuprofen in terms of incidence or ex-
acerbation of asthma in children is based on five RCTs.
As there were paucity of research in this area, high qual-
ity trials with clear definition of asthma outcomes after
receiving ibuprofen or paracetamol at varying doses with
longer follow-up are warranted.
Fig. 2 Forest plot of the Peto’s odds ratio of asthma in children who received paracetamol compared to ibuprofen
Fig. 3 Doi plot and LFK index for the detection of publication bias
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